戻る Agenda
Session 5: Access to Clinical Trials and Post-Marketing Equity for Traditionally Underrepresented Populations: What are Best Practices?
Session Chair(s)
Charlotte Jones-Burton, MD, MS
Vice President
Otsuka Pharmaceutical, United States
Post-marketing and pharmacovigilance efforts are important to ensure the safety and efficacy of an approved drug or biologic. COVID-19 has disproportionately impacted traditionally underrepresented populations and post-market monitoring is lending insight to how these populations are responding to available products. This session will focus on best practices with respect to access to clinical trials and post-marketing equity for traditionally underrepresented populations. The following questions will be explored in this session: How do we engage and ensure health equity and access to traditionally underrepresented populations? Who is the trusted messenger and what is the fix when things do not go right?
Learning Objective : At the conclusion of this session, participants should be able to:
- Discuss how to engage and support health equity and access during the post-marketing phase of the drug development lifecycle
- Identify the trusted messenger within the community they are looking to engage
- Recognize solutions to support health equity and access post-marketing
Speaker(s)
Panelists
Sunita Dhar, DrMed
Genentech, United States
Executive Medical Group Director
Panelist
Lionel Phillips, MBA
Inside Edge Consulting, United States
President